Table 3.
The distribution features of ER/PR/HER2/Ki67 and molecular subtypes in the different age groups
| Parameters | No. of patients (%) | X2 | P values | |||
| All patients (n=1042) |
20–40 years (n=115) | 41–60 years (n=599) |
≥61 years (n=328) |
|||
| ER status | 3.293 | 0.510 | ||||
| Positive expression | 670 (64.3) | 68 (59.1) | 384 (64.1) | 218 (66.5) | ||
| Negative expression | 216 (20.7) | 24 (20.9) | 128 (21.4) | 64 (19.5) | ||
| Not detected | 156 (15.0) | 23 (20.0) | 87 (14.5) | 46 (14.0) | ||
| PR status | 9.411 | 0.152 | ||||
| High expression | 456 (43.8) | 54 (47.0) | 257 (42.9) | 145 (44.2) | ||
| Low expression | 105 (10.1) | 5 (4.3) | 64 (10.7) | 36 (10.8) | ||
| Negative expression | 314 (30.1) | 30 (26.1) | 189 (31.6) | 95 (29.0) | ||
| Not detected | 167 (16.0) | 26 (22.6) | 89 (14.9) | 52 (15.9) | ||
| HER2 status | 10.380 | 0.110 | ||||
| Positive expression | 196 (18.8) | 17 (14.8) | 128 (21.4) | 51 (15.5) | ||
| Negative expression | 627 (60.2) | 65 (56.5) | 351 (58.6) | 211 (64.3) | ||
| Not detected | 219 (21.0) | 33 (28.7) | 120 (20.0) | 66 (20.1) | ||
| Ki67 status | 11.302 | 0.023 | ||||
| High expression | 653 (62.7) | 67 (58.3) | 398 (66.4) | 188 (57.3) | ||
| Low expression | 170 (16.3) | 17 (14.8) | 86 (14.4) | 67 (20.4) | ||
| Not detected | 219 (21.0) | 31 (27.0) | 115 (19.2) | 73 (22.3) | ||
| Molecular subtype | 16.93 | 0.031 | ||||
| Unclassified | 166 (15.9) | 25 (21.7) | 88 (14.7) | 53 (16.2) | ||
| Luminal A | 109 (10.5) | 12 (10.4) | 48 (8.0) | 49 (14.9) | ||
| Luminal B | 565 (54.2) | 54 (47.0) | 344 (57.4) | 167 (50.9) | ||
| HER2-overexpression | 85 (8.2) | 9 (7.8) | 53 (8.8) | 23 (7.0) | ||
| Basal-like | 117 (11.2) | 15 (13.0) | 66 (11.0) | 36 (11.0) | ||
ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.